(NASDAQ: MYGN ), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk ® Hereditary Cancer Test with RiskScore ® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute. The study by Mabey et al., "Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors," presented a longitudinal clinical validation of MyRisk with RiskScore using data from more than 130,000 women referred for hereditary cancer genetic testing. RiskScore integrates a polygenic risk score (PRS) for all ancestries with the widely used Tyrer-Cuzick model.